Pfizer breakup speculation eclipses dismal earnings
This article was originally published in Scrip
If Pfizer is going to break itself into multiple drug companies, the move appears to be at least more than three years away. That doesn’t diminish the intense interest the company created by announcing a business reorganization this week.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.